All In Biotech

Drug Trial Radar · NCT05761223

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB849 Administered in Subjects With Advanced Solid Tumors Alone and in Combination With Pembrolizumab

Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

151

Planned (sponsor's estimate)

Start

Dec 13, 2023

Primary completion

Jun 2026

Study completion Oct 2026

Sponsor

Lead sponsor
1ST Biotherapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is available.

Conditions

  • Advanced Solid Tumor

Interventions

  • Phase Ia dose-escalation part of FB849 MonotherapyDrug

    At a given level dose once daily

  • Phase Ib dose-expansion of FB849 monotherapyDrug

    At recommended dose for expansion cohort once daily

  • Phase IIb dose-escalation part of FB849 in Combination with PembrolizumabDrug

    At recommended dose for expansion cohort once daily in combination with pembrolizumab

  • Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)Drug

    At recommended dose for expansion cohort once daily in combination with pembrolizumab

  • Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)Drug

    At recommended dose for expansion cohort once daily in combination with pembrolizumab

  • Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)Drug

    At recommended dose for expansion cohort once daily in combination with pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of FB849 and to identify maximum tolerated dose (MTD)/ recommended Phase II dose (RP2D) and dosing schedule of FB849 in subjects with advanced solid tumorsTime frame: DLT Assessment at the end of Cycle 1(each cycle is 21 days.)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Mary Crowley Cancer Research Center

    Dallas, Texas · Recruiting

  • NEXT Oncology San Antonio

    San Antonio, Texas · Recruiting

  • Next Oncology Virginia

    Fairfax, Virginia · Recruiting

  • Summit Cancer Centers - Spokane Valley

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.